Silvana Pannain, MD, is a skilled endocrinologist. She provides advanced endocrinology care for patients who have weight problems, endocrine disorders or obesity.
Dr. Pannain serves as director of Chicago Weight, a multidisciplinary weight loss program at the University of Chicago Medicine. She works closely with teams of specialists — including behavior therapists, dietitians, exercise therapists, bariatric surgeons, cardiologists, lipidologists, hypertension specialists and sleep specialists — to develop comprehensive weight management plans for adult patients. These multidisciplinary teams combine counseling and medical treatment options to help patients lose weight. The Chicago Weight program also teaches patients to maintain a healthy lifestyle by permanently changing diet, exercise and behaviors.
Dr. Pannain's clinical and research interests include obesity, metabolic syndrome and related health conditions, such as obstructive sleep apnea and diabetes. She investigates the metabolic and endocrine aspects of chronic partial sleep loss, which is generally considered a risk factor for obesity and insulin resistance.
GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.
GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study. J Addict Med. 2025 Aug 12.
PMID: 40792626
The People-First Liver Charter.
The People-First Liver Charter. Nat Med. 2025 Jul; 31(7):2109-2116.
PMID: 40473951
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United States.
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United States. Hepatol Commun. 2025 May 01; 9(5).
PMID: 40331869
The Role of GLP-1 Agonists in Mitigating Lorlatinib-Induced Metabolic Syndrome: Two Case Studies.
The Role of GLP-1 Agonists in Mitigating Lorlatinib-Induced Metabolic Syndrome: Two Case Studies. Clin Lung Cancer. 2025 Jul; 26(5):429-433.
PMID: 40157899
Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.
Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2024 Dec; 69(12):4437-4445.
PMID: 39516435
Dysregulated 24 h melatonin secretion associated with intrinsically photosensitive retinal ganglion cell function in diabetic retinopathy: a cross-sectional study.
Dysregulated 24 h melatonin secretion associated with intrinsically photosensitive retinal ganglion cell function in diabetic retinopathy: a cross-sectional study. Diabetologia. 2024 Jun; 67(6):1114-1121.
PMID: 38413436
Multidimensional sleep health and diabetic retinopathy: Systematic review and meta-analysis.
Multidimensional sleep health and diabetic retinopathy: Systematic review and meta-analysis. Sleep Med Rev. 2024 04; 74:101891.
PMID: 38118339
Greater sleep variability is associated with higher systemic inflammation in type 2 diabetes.
Greater sleep variability is associated with higher systemic inflammation in type 2 diabetes. J Sleep Res. 2024 05; 33(3):e13989.
PMID: 37414725
Pharmacotherapy of obesity in complex diseases.
Pharmacotherapy of obesity in complex diseases. Clin Obes. 2022 Feb; 12(1):e12497.
PMID: 34889046
Association between Timing of Energy Intake and Insulin Sensitivity: A Cross-Sectional Study.
Association between Timing of Energy Intake and Insulin Sensitivity: A Cross-Sectional Study. Nutrients. 2020 Feb 16; 12(2).
PMID: 32079066